Reported Earlier, United Therapeutics Prevails In Delaware Court Ruling Finding Liquidia Infringes Two Claims Of Patent On Inhaled Treprostinil For PH-ILD Via Yutrepia Marketing
As a result of the Court’s decision, United Therapeutics believes that it is entitled to an order instructing the U.S. Food and Drug Administration (FDA) to withdraw approval of Liquidia’s new drug application (NDA) for
A judge said Liquidia copied United Therapeutics' medicine idea. United thinks the FDA should stop selling Liquidia's drug because of this.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.